Trial Profile
Imatinib Mesylate (Glivec) as Maintenance Therapy After Cytogenetic Response With Nilotinib (AMN107, Tasigna) First Line in Newly Diagnosed Chronic Myelogenous Leukemia.
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 02 Feb 2024
Price :
$35
*
At a glance
- Drugs Imatinib (Primary) ; Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 30 Jan 2024 Planned End Date changed from 1 Jul 2023 to 1 Jul 2025.
- 30 Jan 2024 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2025.
- 14 Feb 2022 Planned End Date changed from 1 Jul 2022 to 1 Jul 2023.